Collegium Pharmaceutical (NASDAQ:COLL) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Collegium Pharmaceutical (NASDAQ:COLL - Free Report) from a buy rating to a strong-buy rating in a research report sent to investors on Saturday morning.

Other equities analysts have also recently issued research reports about the company. Piper Sandler reissued a "neutral" rating and set a $37.00 price objective (up previously from $36.00) on shares of Collegium Pharmaceutical in a research report on Friday, May 9th. HC Wainwright reissued a "buy" rating and set a $50.00 price objective on shares of Collegium Pharmaceutical in a report on Monday, March 24th. Finally, Needham & Company LLC restated a "buy" rating and set a $46.00 price target on shares of Collegium Pharmaceutical in a research report on Wednesday, April 9th. One research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Collegium Pharmaceutical has an average rating of "Buy" and a consensus price target of $43.75.

Collegium Pharmaceutical Stock Up 0.8%

Shares of COLL stock traded up $0.23 on Friday, hitting $30.11. The company's stock had a trading volume of 225,792 shares, compared to its average volume of 403,981. The company has a debt-to-equity ratio of 3.30, a current ratio of 1.08 and a quick ratio of 1.01. The stock has a market capitalization of $967.43 million, a price-to-earnings ratio of 24.68 and a beta of 0.63. Collegium Pharmaceutical has a fifty-two week low of $23.23 and a fifty-two week high of $42.29. The firm's fifty day moving average price is $28.63 and its 200-day moving average price is $29.52.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The specialty pharmaceutical company reported $1.49 EPS for the quarter, missing analysts' consensus estimates of $1.50 by ($0.01). Collegium Pharmaceutical had a net margin of 6.61% and a return on equity of 99.08%. The company had revenue of $177.76 million for the quarter, compared to analyst estimates of $174.96 million. During the same period in the prior year, the company posted $1.45 EPS. The business's revenue was up 22.7% on a year-over-year basis. Research analysts anticipate that Collegium Pharmaceutical will post 5.62 EPS for the current year.

Insider Activity

In other Collegium Pharmaceutical news, Director John Gordon Freund sold 6,601 shares of the business's stock in a transaction dated Monday, June 9th. The stock was sold at an average price of $30.62, for a total transaction of $202,122.62. Following the completion of the sale, the director now directly owns 70,658 shares of the company's stock, valued at approximately $2,163,547.96. The trade was a 8.54% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 2.51% of the stock is owned by insiders.

Institutional Investors Weigh In On Collegium Pharmaceutical

A number of institutional investors and hedge funds have recently modified their holdings of the business. Millennium Management LLC grew its holdings in Collegium Pharmaceutical by 248.5% during the first quarter. Millennium Management LLC now owns 647,832 shares of the specialty pharmaceutical company's stock valued at $19,338,000 after purchasing an additional 461,914 shares during the period. Invesco Ltd. grew its holdings in shares of Collegium Pharmaceutical by 19.5% in the 4th quarter. Invesco Ltd. now owns 1,775,760 shares of the specialty pharmaceutical company's stock valued at $50,876,000 after acquiring an additional 289,335 shares in the last quarter. Janus Henderson Group PLC grew its stake in Collegium Pharmaceutical by 319.4% in the fourth quarter. Janus Henderson Group PLC now owns 291,388 shares of the specialty pharmaceutical company's stock valued at $8,341,000 after purchasing an additional 221,903 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in Collegium Pharmaceutical during the fourth quarter worth $3,489,000. Finally, Massachusetts Financial Services Co. MA raised its position in Collegium Pharmaceutical by 18.1% during the first quarter. Massachusetts Financial Services Co. MA now owns 713,854 shares of the specialty pharmaceutical company's stock worth $21,309,000 after acquiring an additional 109,655 shares in the last quarter.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.